Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
Pathol Res Pract. 2020 May;216(5):152941. doi: 10.1016/j.prp.2020.152941. Epub 2020 Mar 28.
CDH1 mutation is the most frequent genetic alteration in hereditary diffuse gastric cancer (GC) and early onset diffuse GC patients. However, the incidence of CDH1 mutations in sporadic GC with or without family history has not been studied. This retrospective study includes a total of 993 Korean patients with primary advanced GC who underwent surgery and received palliative chemotherapy. Targeted deep sequencing was performed in all cases and family history of GC was searched with survival analysis. We found CDH1 alterations in 146 of 993 patients (14.7 %) and 8 were germline (0.8 %). Out of 146 patients with CDH1 mutations, 25 (17.1 %) had a family history of GC in one of their first relatives, and 12 patients (8.2 %) were diagnosed with familial GC (FGC). All cases with FGC were diffuse type by Lauren classification, and only one harbored a previously reported germline mutation of CDH1 (c.2638 G > A) and the remaining 11 harbored known somatic CDH1 mutations. Among all patients with CDH1 mutation, there was no significant survival difference between patients with family history or FGC. In the 847 patients without CDH1 mutation, 189 (22.3 %) had a family history of GC and 92 patients (10.9 %) were FGC. CDH1 mutations were more frequent in patients with early onset (<45 years) GC (45.5 %) compared with patients with late onset GC (10.9 %) (p = 0.001), but were not significantly associated with the family history of GC (p > 0.05). CDH1 mutations are mostly somatic and typically are not associated with family history.
CDH1 突变是遗传性弥漫性胃癌(GC)和早发性弥漫性 GC 患者中最常见的遗传改变。然而,散发性 GC 患者中是否存在 CDH1 突变,无论其是否有家族史,尚未得到研究。本回顾性研究共纳入 993 例韩国原发性晚期 GC 患者,所有患者均接受手术治疗和姑息性化疗。所有病例均进行靶向深度测序,并通过生存分析寻找 GC 家族史。我们在 993 例患者中发现 146 例(14.7%)存在 CDH1 改变,其中 8 例为种系突变(0.8%)。在 146 例 CDH1 突变患者中,25 例(17.1%)有直系亲属中的 GC 家族史,12 例(8.2%)被诊断为家族性 GC(FGC)。所有 FGC 病例均为 Lauren 分类的弥漫型,且仅有 1 例存在先前报道的 CDH1 种系突变(c.2638G>A),其余 11 例存在已知的 CDH1 体细胞突变。在所有 CDH1 突变患者中,有家族史或 FGC 的患者之间的生存无显著差异。在 847 例无 CDH1 突变的患者中,189 例(22.3%)有 GC 家族史,92 例(10.9%)为 FGC。与发病较晚(>45 岁)的 GC 患者相比,发病较早(<45 岁)的 GC 患者中 CDH1 突变更为常见(45.5%比 10.9%,p=0.001),但与 GC 家族史无显著相关性(p>0.05)。CDH1 突变主要为体细胞突变,且通常与家族史无关。